Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: Is it safe even in cancer patients?

Anti-Cancer Drugs

Volumn 24, Issue 10, 2013, Pages 989-998

  Del Pup, Lino ^a   Di Francia, Raffaele ^b   Cavaliere, Carla ^b   Facchini, Gaetano ^b   Giorda, Giorgio ^a   De Paoli, Paolo ^a   Berretta, Massimiliano ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

absorption; cancer; promestriene; systemic effects; vaginal atrophy; vaginal estrogens

Indexed keywords

ANASTROZOLE; CHENODEOXYCHOLIC ACID; CONJUGATED ESTROGEN; CORTICOSTEROID; CYPROTERONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DEFERASIROX; ESTRADIOL; ESTRIOL; ESTRONE; FOLLITROPIN; GONADOTROPIN; HUMAN GROWTH HORMONE; HYALURONIDASE; LUTEINIZING HORMONE; PLACEBO; PROMESTRIENE; ROPINIROLE; SAXAGLIPTIN; TIPRANAVIR; URSODEOXYCHOLIC ACID;

ABSENCE OF SIDE EFFECTS; CANCER PATIENT; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPAREUNIA; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAINTENANCE THERAPY; MASTALGIA; OUTCOME ASSESSMENT; PATIENT SAFETY; PERINEAL PAIN; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT DURATION; UTERUS BLEEDING; VAGINA ATROPHY; VAGINA CYTOLOGY; VAGINAL DRYNESS; VAGINAL LUBRICATION;

ADMINISTRATION, INTRAVAGINAL; ATROPHY; CLINICAL TRIALS AS TOPIC; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NEOPLASMS; TREATMENT OUTCOME; VAGINA;

EID: 84885344365     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328365288e     Document Type: Review

References (77)

1. Kao A, Binik YM, Kapuscinski A, Khalife? S. Dyspareunia in postmenopausal women: A critical review. Pain Res Manag 2008; 13:243-254.
2. Al-Baghdadi O, Ewies AAA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: An up-to-date overview. Climacteric 2009; 12:91-105.
3. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; 18:CD001500.
4. Nappi RE, Nijland EA. Women's perspective of sexuality around the menopause: Outcomes of a European telephone survey. Eur J Obstet Gynecol Reprod Biol 2008; 137:10-16.
5. De Aloysio D, Pennacchioni P, Bonino S. Rational use of vaginal promestriene. Ital J Obstet Gynecol 1995; 9:533-538.
6. Belaish J, Thomas JL, Becker JF, Lumbroso M. French and European experience with promestriene. In: Bottiglioni F, editor. Female climateric. Pavia, Italy: Torchio De Ricci; 1988. pp. 29-44.
7. Santos I, Clissold S. Urogenital disorders associated with oestrogen deficiency: The role of promestriene as topical oestrogen therapy. Gynecol Endocrinol 2010; 26:644-651.
8. Opinel P, Le Hors H, Tramier D, Inguimbert M, Audibert M, Cassin D. Hematocolpometra and local estrogen therapy: An overdose of promestriene? J Gynecol Obstet Biol Reprod 1991; 20:60-62.
9. Vors J, Muller P. Tropicità vaginale e colpotrophine. Gen Med 1975; 1:1-3.
10. Campana G, Di Francesco G. Climateric syndrome: Clinical experiences with promestriene. Ann Obstet Gynecol Perinat Med 1976; 97:189-198.
11. Gaudefroy M, Pigache JP. Study of estrogenic effects of promestriene. Arch Anat Cytol Pathol 1977; 25:125-128.
12. Villani L, Romanini C, Fornara CF, et al. Trophic disorders in gynecology seniors. Clinical aspects, index vulvar pathology, vaginal and cervical. Action promestriene. Medicine and 3rd Age 1978; 1:315-321.
13. Romanini C, Villani L, Pasqua M, Gaglione R, Fischetti C, Fornara CF. Prolonged treatment of atrophic vaginitis by promestriene. Results and tolerance. Gynecology 1980; 31:627-631.
14. Wurch T, Bursaux CD, Cohen A. Promestriene interest in the treatment of postmenopausal atrophic vaginitis. Gynecology 1981; 32:551-556.
15. Wolff JP, Cachelou R, Gueritee N. Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa. Maturitas 1982; 4:239-246.
16. Wolff JP, Cachelou R. Sexual dysfunction secondary to gynecological cancer. Their local treatment diether estradiol without systemic hormonal activities. French Gynecol Obst Rev 1983; 78:189-194.
17. Moore DH, Chasseaud LF, Darragh A, Taylor T, Cresswell DG. The percutaneous absorption and excretion of promestriene [3-propoxy-17beta-methoxy- 1,3,5[10]-estratriene] in rats and humans. Steroids 1983; 41:15-22.
18. Palacios SJ, Uribe L, Fernandez Villoria E. Local and systemic effects after the intravaginal administration of estrogens (Promestrien) in menopausal women. Presented at the XIth World Congress of Gynaecology and Obstetrics, 15-20 September, Berlin, Germany; 1985.
19. Arvis G, Bensadoun R, Lecourt R, Pfeffer H, Sintes G. Promestriene interest in the treatment of voiding dysfunction in postmenopausal. French Gynecol Obst Rev 1986; 81:727-729.
20. Romanini C, Paparatti L, Finelli FG. Local and systemic estrogenic activity of the topics used to treat vaginal atrophy. Med Hyg 1986; 44:1562-1568.
21. Colle M, Broussin B. Sonographic changes in the immature uterus under the influence of estrogen treatment. Ann Pediatr (Paris) 1987; 34:611-614.
22. Palacios Gil Antunano S, Peralta J, Mujica I, Fernandez Villoria E. Assessing estradiol diether systemic effects in premenopausal and postmenopausal women. Presented at the 19th National Congress of Gynecology, 22-24 October, Oviedo, Spain; 1987.
23. Wurch TA, Lumbroso M, Becker JF. Getting evidence of the lack of systemic effect promestriene used at high doses. Gynecocology 1988; 39:101-103.
24. Wurch T, Thomas JL, Lumbroso M. Comparison between the effects of two estrogens administered by the vaginal route on the vagina of postmenopausal women. Contracept Fertil Sex 1988; 15:313-315.
25. Cecchini G, Zaffaroni L, Zacchi V, Bini M, Ferutta P. Effectiveness of replacement therapy in local processes regressive deficiency of the female genitalia: Estriol v/s promestriene. Lower genital tract pathology of menopausal women; 9-11 September 1991; Castrovillari (Italy).
26. Castrovillari (Italy)
27. Marchesoni D. In: Torchio De i Ricci, editor. Vaginal atrophy symptoms. Open label study of vaginal promestriene. Bologna, Italy; 1988. pp. 51-53.
28. Borrelli AL, Casolaro AM, Espó sito G, Berlingieri D. Biological activity of promestriene on the genital tract of ovariectomized rat. Minerva Gynecol 1990; 42:467-472.
29. Perino A, Catinella E, Costa P, Palmieri MA, et al. Evaluation of endometrial receptor in patients treated with topical promestriene. Contracept Fertil Sex 1990; 17:245-250.
30. Lepore G, Nosari I, Maglio ML, Pagani G. Effects of topical promestriene on glucose and lipid metabolism in diabetic patients with post menopausal vaginal atrophy. Contracept Fertil Sex 1990; 17:559-562.
31. Carbonaro A, Boemi G, Zizza G, Santangelo R. Vaginal delivery of promestriene and post menopausal stress incontinence. Contracept Fertil Sex 1990; 17:257-258.
32. Primiero FM, Bastinanelli C, Grottanelli F, Tunnera G, Pagliarella MR, et al. Evaluation of estrogen induced effects from a topical estrogen in the treatment of vulvar, cervical an vaginal atrophy. Rome: CIC; 1990. pp. 151-156.
33. Mignano P, Spallone A, D'Amato F, Aprea C, Vigilante M. Promestriene use in the treatment of multiple vaginal delivery lesions. Contracept Fertil Sex 1991; 18:325-328.
34. Colau JC, Corette L, Laffargue F, Lerat MF, Ritter J, Fenichel P, et al. Clinical and cytological efficacy of promestriene. Gynecol Obstet Rev 1991; 2:67-72.
35. De Punzio C, Maio A, Metelli P, Neri E, Bagnoni G, Fioretti P. Therapeutic strategies in recurrent vaginitis: Efficacy of promestriene. Int J Gynecol Obstet 1992; 1:1-8.
36. Perino A, Chianchiano N, Simonaro C, Biondo A, Palmieri MA, Petronio M. Use of promestriene in the prevention of side effects during treatment with GnRH analogues. Int J Gynecol Obstet 1992; 4:160-163.
37. Panarello S, Borrelli A. Topical estrogen treatment with promestriene of the vulvo-vaginal atrophy lesions from hypoestrogenism in diabetic patients. Third Age Gynecology. SIGITE Congress Acts. Capri, Italy; 1992. pp. 3-8.
38. Bonneton A, De chaud H, Fleury MC, Colau JC, Pugeat M. Lack of influence of promestriene vaginally administered on circulating levels of hormones and estrogen dependent hepatic proteins in postmenopausal women. Gynecocology 1992; 43:45-48.
39. Bruni M, Amuso G, Ruggeri E, et al. Topical treatment of post menopausal atrophy of lower genital tract. Comparative study between estriol and promestiene. Contracept Fertil Sex 1992; 19:317-321.
40. De Puzio C, Maio A, Metelli P, et al. Effectiveness of promestriene in recurrent vaginitis. Int J Gynecol Obstet 1993; 2:59-63.
41. Tinelli A, Malvasi A, D'Anna L, Tinelli R, Perrone A, Tinelli FG. Presurgical promestriene therapy in postmenopausal women with stress urinary incontinence. Gynecol Endocrinol 2007; 23:445-450.
42. Grossi F, Goisis F, Grassini E, Cellani F. Topical promestriene in the vulvo, cervical and vaginal menopausal atrophy treatment. Contracept Fertil Sex 1993; 20:245-247.
43. Minini FG, Paganotti C, Roggia A, Moretti R. Clinical and urodinamic effects of promestriene on stress urinary incontinence in menopause. Urogynecol Int J 1993; 7:25-32.
44. Cervigni M, Ciardi A, Panei M, Scotto V, Sbiroli C. Use of promestriene in the treatment of urogynecologic disorders in postmenopausal women. Urogynecol Int J 1994; 8:109-118.
45. De Aloysio D, Altieri P, Gori GF, et al. Vaginal estrogen before and after gynecologic and urogynecologic surgery. XXXV AOGOI Congress Acts. Naples. 1994.
46. Cristiani P, Abruzzese A, Benedetti M, et al. Management of ASCUS in postmenopausal women. In: Monsonego J, editor. Proceedings of 5th Int. Multidisc. Concress Eurogyn 2003. Bologna: Monduzzi Int. Proc Division; 2003. pp. 241-244.
47. Piccoli R, Mandato VD, Lavitola G, Acunzo G, Bifulco G, Tommaselli GA, et al. Atypical squamous cells and low squamous intraepithelial lesions in postmenopausal women: Implications for management. Eur J Obstet Gynecol Reprod Biol 2008; 140:269-274.
48. Bruno R, Silveira F, Costa K, Ormand J, Postruznik D. Comparative trial between promestriene and estriol vaginal creams: Analysis after six continuous months. Maturitas 2009; 2 (Suppl 1):529.
49. Del Pup L, Postruznik D. Can promestriene be used even in oncology patients? Proceedings 14th World Congress on COGI. Paris, France: Monduzzi Ed. 2012. pp. 213-217.
50. Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: A pilot study. Maturitas 2012; 72:93-94.
51. Del Pup L. Vaginal estrogen therapy for oncological patients: Practical advice to improve investigations adequacy and quality of life. Gynecol Endocrinol Bull 2010; 4:68-73.
52. Del Pup L. Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients. Gynecol Endocrinol 2012; 28:740-745.
53. Sun AJ, Lin SQ, Jing LH,Wang ZY, Ye JL, Zhang Y. Safety of promestriene capsule used in postmenopausal atrophic vaginitis. Zhonghua Fu Chan Ke Za Zhi 2009; 44:593-596.
54. Pschera B, Hjerpe A, Carltrom K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 and progesterone in postmenopausal women. Gynecol Obstet Invest 1989; 27:204-208.
55. Rigg LA, Hermann H, Yen SC. Absorption of estrogens from vaginal creams. N Engl J Med 1978; 298:195-197.
56. Corona G, Elia C, Casetta B, Da Ponte A, Del Pup L, Ottavian E, Toffoli G. Liquid chromatography tandem mass spectrometry assay for fast and sensitive quantification of estrone-sulfate. Clin Chim Acta 2010; 411:574-580.
57. Dowsett M, Folkerd E. De ficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 2005; 7:1-4.
58. Jones ME, Folkerd EJ, Doody DA, Iqbal J, Dowsett M, Ashworth A, Swerdlow AJ. Effect of delays in processing blood samples on measured endogenous plasma sex hormone levels in women. Cancer Epidemiol Biomarkers Prev 2007; 16:1136-1139.
59. Toniolo P, Lukanova A. The challenge of measuring circulating estradiol at low concentrations. Breast Cancer Res 2005; 7:45-47.
60. Sitruk-Ware R, Thomas JL. Local hormonal treatment of vaginal atropy. France: Praxis Editions; 1997. pp. 1245-1248.
61. Tresca JP, Ponsard G, De grelle H, Jayle MF. Study of the metabolism of 3-propi-ether of estradiol beta estradiol versus 17beta in the perfused rat liver. Can J Biochem 1978; 56:985-992.
62. Thomas JL, Mignot A, Roger M, Guillaume M. Compared absorption of promestriene by vaginal and oral routes in postmenopausal women. Presented as a poster at the 9th International Congress of Endocrinology August-5 September, Nice, France; 1992.
63. Fraser IS,Wang Y. New delivery systems for hormone replacement therapy. In: Wren BG, editor. Progress in the Management of the Menopause. Carnforth, UK: Parthenon Publishing; 1997. pp. 58-67.
64. Nash HA, Brache V, Alvarez-Sanchez F, Jackanicz TM, Harmon TM. Estradiol delivery by vaginal rings: Potential for hormone replacement therapy. Maturitas 1997; 26:27-33.
65. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Natl Cancer Inst 2000; 92:1054-1064.
66. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6:45-52.
67. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17:584-587.
68. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJA. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802.
69. Rosenberg LU, Magnusson C, Lindstrom E,Wedrén S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: A case-control study. Breast Cancer Res 2006; 8:R11.
70. Trinkaus M, Chin S,Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008; 13:222-231.
71. Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M, et al. The De tection and management of vaginal atrophy. J Obstet Gynaecol Can 2004; 26:503-515.
72. ASCUS LSIL Triage Study Group. Predicting absolute risk of CIN3 during post-colposcopic follow-up: Results from the ASCUS-LSIL Triage Study [ALTS]. Am J Obstet Gynecol 2006; 195:341-348.
73. Labrie F, Cusan L, Gomez JL, Coté I, Berubé R, Belanger P, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009; 16:30-36.
74. Kobata SA, MJBC Girã o, Baracat EC, Kajikawa M, Di Bella V Jr, Sartor MGF, Jármy-Di Bella ZIK. Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Doppler velocimetry analysis. Maturitas 2008; 61:243-247.
75. Luciano Mariani L, Gadducci A, Vizza E, Tomao S, Vici P. Vaginal atrophy in breast cancer survivors: Role of vaginal estrogen therapy. Gynecol Endocrinol 2013; 29:25-29.
76. Sturdee DW, Panay N. International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13:509-522.
77. The North American Menopause Society (NAMS). Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Position Statement. Menopause 2010; 17:242-255.